Skip to main content
. 2022 Jun 6;40(34):3952–3964. doi: 10.1200/JCO.22.01003

FIG A2.

FIG A2.

PFS by blinded independent central review in (A) patients with BRCA-mutant tumors, (B) patients with BRCA wild-type/LOH high tumors, and (C) patients in the homologous recombination deficiency-negative subgroup (BRCA wild-type/LOH low tumors). BRCA, BRCA1 or BRCA2; HR, hazard ratio; LOH, loss of heterozygosity; NR, not reached; PFS, progression-free survival.